X

WHY BLOOM BURTON & CO?
SERVICES
TRANSACTIONS
TEAM
EVENTS
News & Insights
CAREERS
CONTACT

•

M

E

N

U

•

March 31, 2016

Bloom Burton’s analyst David Martin speaks to BNN about Concordia's latest earnings

Click on the image to view the full video.

RELATED NEWS

Satellos Announces Closing of US$40M Public Offering The Globe and Mail | Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval Titan Announces the Closing of Conavi’s Private Placement of Subscription Receipts and Provides Update on the Transaction Roberto Bellini Receives the 2024 Bloom Burton Award The Globe and Mail | Ex-Chinook team launches Borealis Biosciences with $150-million from Novartis, Versant Hamilton City Magazine | Coming to life at McMaster University Acquisition of Fusion Pharmaceuticals Completed Three Finalists Announced for the 2024 Bloom Burton Award The Globe and Mail | LSD, Ecstasy, magic mushrooms coming to a clinic near you? Legalization nears for psychedelics Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader

2025 BLOOM BURTON & CO DESIGNED & DEVELOPED BY THE TEAM AT PIXELCARVE MEMBER CIRO MEMBER CIPF PRIVACY POLICY COMPLAINT BEST EXECUTION POLICY ACCESSIBILITY POLICY BUSINESS CONTINUITY PLAN LEGAL DISCLAIMER CONFLICTS OF INTEREST